Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3‐year period population‐based prospective cohort study
- 15 May 2020
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (12) , 2519-2529
Abstract
Aims: The objective was to compare major bleeding risk of direct oral anticoagulants (DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication, using real‐world data.Methods: A population‐based prospective cohort study, using the French national health data system (SNIIRAM), identified 47 469 adults living within 5 well‐defined geographical areas, who were new users of oral anticoagulants in the period 2013–2015: 20 205 VKA users, 19 579 rivaroxaban users, 4225 dabigatran users and 3460 apixaban users. From all emergency departments within these areas, clinical data for all adults referred for bleeding was collected and medically validated. The databases were linked for common key variables. The main outcome measure was major bleeding: intracranial haemorrhage, major gastrointestinal bleeding and other major bleeding events. Hazard ratios were derived from adjusted Cox proportional hazard models. We used propensity score weighting as a sensitivity analysis, with separate analyses according to indications (atrial fibrillation or venous thromboembolism).Results: Compared to VKAs, high and low‐dose DOACs were associated with a reduced risk of intracranial haemorrhage (adjusted hazard ratio 0.55, 95% confidence interval 0.37–0.82 and 0.54, 0.26–1.12 respectively), and a reduced risk of other major bleeding events (0.41, 0.29–0.58 and 0.41, 0.22–0.79 respectively), irrespective of duration and indication. Neither DOAC dose evidenced any significant difference from VKAs in terms of risk of major gastrointestinal bleeding.Conclusion: There is a clear benefit of using DOACs with regard to intracranial haemorrhage. The study provides new insight into major gastrointestinal and other major bleeding events.Keywords
This publication has 52 references indexed in Scilit:
- Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial FibrillationThe American Journal of Medicine, 2014
- Effect of warfarin on intracranial hemorrhage incidence and fatal outcomesThrombosis Research, 2013
- Oral Anticoagulant TherapyChest, 2012
- Emergency Hospitalizations for Adverse Drug Events in Older AmericansNew England Journal of Medicine, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial FibrillationChest, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Constructing Inverse Probability Weights for Marginal Structural ModelsAmerican Journal of Epidemiology, 2008